BioLife CTO awarded 24,116 restricted shares

Werner Sean reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Werner Sean reported acquisition or exercise transactions in this Form 4 filing.

BioLife Solutions Chief Technology Officer Sean Werner received a grant of 24,116 shares of common stock as part of his 2026 compensation. The restricted stock was issued under the 2023 Omnibus Performance Incentive Plan and will vest 25% on the first anniversary of the grant date, then in 12 equal quarterly installments. Following this award, he directly holds 50,043 shares of common stock.

Insider Trade Summary

Grant/Award: 24,116 shares

Grant/Award 1 txn

Insider Werner Sean

Role Chief Technology Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	24,116	$0.00	$0.00

Holdings After Transaction: Common Stock — 50,043 shares (Direct)

Footnotes (1)

1. F1. The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2026 compensation.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did BioLife Solutions (BLFS) disclose about Sean Werner in this Form 4?

BioLife Solutions reported that Chief Technology Officer Sean Werner received a grant of 24,116 shares of restricted common stock. The award was made as part of his 2026 compensation under the company’s 2023 Omnibus Performance Incentive Plan.

How many BioLife Solutions (BLFS) shares does Sean Werner hold after this grant?

After the restricted stock grant, Chief Technology Officer Sean Werner directly owns 50,043 shares of BioLife Solutions common stock. This figure reflects his holdings immediately following the 24,116-share award reported in the Form 4 filing.

What is the vesting schedule for Sean Werner’s new BLFS restricted stock?

The restricted stock vests 25% on the first anniversary of the grant date, then in 12 equal quarterly installments. This schedule gradually delivers the full 24,116-share award over time, aligning with the BioLife Solutions 2023 Omnibus Performance Incentive Plan.

Was cash paid for the BioLife Solutions (BLFS) shares granted to Sean Werner?

No cash was paid for this grant; the reported price per share is 0.0000. The 24,116 restricted shares were issued as an equity component of Sean Werner’s 2026 compensation under BioLife Solutions’ 2023 Omnibus Performance Incentive Plan.

Under which plan were the BLFS restricted shares granted to Sean Werner?

The restricted shares were granted under the BioLife Solutions 2023 Omnibus Performance Incentive Plan. This plan authorizes equity-based awards, and the 24,116-share grant forms part of Chief Technology Officer Sean Werner’s compensation for 2026.

Is Sean Werner’s ownership in BioLife Solutions (BLFS) direct or indirect?

Sean Werner’s reported ownership is direct, as indicated by the direct ownership code "D" in the Form 4. The 50,043 shares of common stock following the transaction are held directly rather than through an intermediary entity or trust.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/26/2026 - 05:55 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Werner Sean

(Last) (First) (Middle)

3303 MONTE VILLA PARKWAY

SUITE 310

(Street)

BOTHELL WA 98021

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOLIFE SOLUTIONS INC [ BLFS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Technology Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/24/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/24/2026		A		24,116	A	(1)	50,043	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The restricted stock was granted pursuant to the BioLife Solutions 2023 Omnibus Performance Incentive Plan and vests 25% on the first anniversary of the grant date and thereafter quarterly, in 12 equal quarterly installments. The restricted stock was granted to the reporting person as part of 2026 compensation.

Remarks:

	/s/ Sean Werner	02/26/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.